Remove FDA Remove Patients Remove Retail
article thumbnail

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

Biogen shot up when an initial review of their Alzheimer’s drug was positive, but then analysts torpedoed the company when another FDA panel said there wasn’t enough data. Our imbecile lame duck President is saying that Pfizer and the FDA conspired to release the news after the election. It’s a never-ending cycle.

Media 286
article thumbnail

How one pharma “family business” places patients first

pharmaphorum

And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. years to win FDA approval, at a median cost of $648 million. It’s Amazon.

Insurance 181
article thumbnail

Walmart follows CVS, Walgreens into clinical trial sector

pharmaphorum

Walmart is the latest US retail pharmacy giant to announce its intention of disrupting the clinical trials category, with the launch of a new institute that pledges to increase and diversify community access to healthcare research.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

For example, the US recently passed the Inflation Reduction Act, 1 which requires the Secretary of Health and Human Services (HHS) to negotiate prices for certain physician-administered and retail prescription drugs covered under Medicare Parts B and D. Citizen Petitions before the FDA. 5) monitoring access to biosimilars.

article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; and 80 percent of studies do not meet enrollment deadlines. Dr. Rizk provided an example of how we’re getting better at meeting patients where they are. Below are highlights and key takeaways from the panel.

article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

Amivantamab is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Retail 40